Details of Disease

General Information of Disease (ID: DISPT4TG)

Disease Name Meningioma
Synonyms
meningeal neoplasm; primary meningeal tumor; supratentorial meningioma; primary meningeal tumour; intracranial meningioma; meningothelial cell tumor; meningothelial cell tumour; meningioma (disease); meningioma
Definition
A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)
Disease Hierarchy
DISOZOR8: Meningioma tumour
DISPT4TG: Meningioma
Disease Identifiers
MONDO ID
MONDO_0016642
MESH ID
D008579
UMLS CUI
C0025286
MedGen ID
7532
HPO ID
HP:0002858
Orphanet ID
2495

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 72 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ALAD TTJHKYD Limited Biomarker [1]
EPHA1 TTLFZVU Limited Biomarker [2]
KIF11 TTBGTCW Limited Biomarker [3]
NEK9 TTM57AW Limited Biomarker [4]
PDGFB TTQA6SX Limited Biomarker [5]
PTEN TTXJ3W7 Limited Biomarker [6]
RHBDF2 TTH1ZOP Limited Biomarker [7]
VSIR TT51SK8 Limited Biomarker [8]
CHEK2 TT9ABMF Disputed Biomarker [9]
CTSL TT36ETB Disputed Biomarker [10]
DNMT1 TT6S2FE Disputed Altered Expression [11]
AKT1 TTWTSCV moderate Biomarker [12]
BRIP1 TTZV7LJ moderate Genetic Variation [13]
CCKAR TTCG0AL moderate Biomarker [14]
CCKBR TTVFO0U moderate Altered Expression [14]
CD70 TTNCIE0 moderate Altered Expression [15]
CPA1 TT3LJ6G moderate Genetic Variation [16]
DPP8 TTJGLZF moderate Altered Expression [17]
DPP9 TTNDUL7 moderate Altered Expression [17]
EGFL6 TTXJGAR moderate Altered Expression [18]
EIF5A TTIVCNR moderate Altered Expression [19]
FCER1G TTDGEC0 moderate Genetic Variation [20]
GRB2 TTEYRJ9 moderate Biomarker [21]
HOXA7 TTMRE4Q moderate Posttranslational Modification [22]
IDO2 TTALN9W moderate Altered Expression [23]
IGFBP6 TTLAYV8 moderate Altered Expression [24]
KLK6 TTLPF4X moderate Altered Expression [25]
MCM6 TTQGKSD moderate Altered Expression [26]
OPHN1 TTU7HRD moderate Altered Expression [27]
PLA2G7 TTDNFMT moderate Altered Expression [28]
PPID TTNAFOU moderate Altered Expression [29]
PPIF TTRFQTB moderate Altered Expression [29]
PRLR TTBPXMA moderate Altered Expression [30]
TAGLN2 TTP6BIJ moderate Altered Expression [31]
TCL1A TTUKRDV moderate Biomarker [32]
TDO2 TTXNCBV moderate Biomarker [33]
TIPARP TT2FRAN moderate Altered Expression [29]
TMEM97 TT9NXW4 moderate Altered Expression [34]
TNKS TTVUSO7 moderate Biomarker [35]
TRPV3 TT946IA moderate Biomarker [36]
VDAC2 TTM1I7L moderate Biomarker [37]
AQP1 TTSF1KH Strong Altered Expression [38]
C1QBP TTWTD7F Strong Genetic Variation [39]
CDKN2C TTBRUGA Strong Biomarker [40]
CTSB TTF2LRI Strong Biomarker [41]
DOT1L TTSZ8T1 Strong Biomarker [42]
F13A1 TTXI2RA Strong Biomarker [43]
KLF4 TTTI53X Strong Genetic Variation [44]
MCM7 TT1RM3F Strong Biomarker [45]
MKI67 TTB4UNG Strong Biomarker [46]
NPY2R TTJ6WK9 Strong Altered Expression [47]
ODC1 TTUMGNO Strong Altered Expression [48]
PLAUR TTNOSTX Strong Altered Expression [49]
PSCA TT9T4AV Strong Altered Expression [50]
RAC3 TT9BQ50 Strong Altered Expression [51]
SMO TT8J1S3 Strong Altered Expression [33]
SST TTWF7UG Strong Biomarker [52]
SSTR2 TTZ6T9E Strong Altered Expression [53]
TGM2 TT2F4OL Strong Biomarker [54]
TOP2A TTCGY2K Strong Biomarker [55]
WRN TT2H5WQ Strong Genetic Variation [13]
ALPL TTMR5UV Definitive Biomarker [56]
ATRAID TTFLIKM Definitive Genetic Variation [57]
CA9 TT2LVK8 Definitive Biomarker [58]
CD276 TT6CQUM Definitive Biomarker [8]
CTAG1A TTE5ITK Definitive Altered Expression [59]
GNRH1 TT0ID4A Definitive Altered Expression [60]
IGFBP5 TTDWEA8 Definitive Altered Expression [61]
PTN TTA9EJK Definitive Altered Expression [62]
PTPRJ TTWMKXP Definitive Biomarker [63]
RPS6KB1 TTG0U4H Definitive Genetic Variation [64]
TXNIP TTTLDZK Definitive Altered Expression [65]
------------------------------------------------------------------------------------
⏷ Show the Full List of 72 DTT(s)
This Disease Is Related to 2 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
ABCA2 DTJ4NEG Limited Biomarker [66]
ABCC5 DTYVM24 moderate Altered Expression [67]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP4F3 DEFCMPI Strong Genetic Variation [68]
MTRR DE6NIY9 Definitive Genetic Variation [69]
PTGDS DER3H9C Definitive Altered Expression [70]
------------------------------------------------------------------------------------
This Disease Is Related to 134 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADAMTSL3 OTMC2WFG Limited Biomarker [71]
ARMC5 OTO7IV74 Limited Altered Expression [72]
CAPN5 OTQ8QM7K Limited Biomarker [71]
KCNIP3 OTCQPEM4 Limited Biomarker [73]
KIF14 OTXHT4JM Limited Altered Expression [3]
KIF20A OTXOQHE0 Limited Biomarker [3]
KIF4A OT3UWL7D Limited Altered Expression [3]
KIFC1 OTNQDS00 Limited Biomarker [3]
MEIS1 OTH9DKAD Limited Biomarker [74]
RDX OTNSYUN6 Limited Biomarker [75]
SMARCE1 OTAX4ITH Limited Genetic Variation [58]
SMG8 OTY9PCZY Limited Biomarker [66]
SUFU OT0IRYG1 Limited Genetic Variation [76]
TCF12 OTZVONNU Limited Biomarker [77]
CST3 OTNZ6AO4 Disputed Biomarker [10]
CSTB OT3U0JF8 Disputed Biomarker [10]
A1BG OTFVUGNQ moderate Altered Expression [78]
AIP OTDJ3OSV moderate Genetic Variation [79]
AKAP12 OTCVRDDX moderate Biomarker [80]
ALDH1A3 OT1C9NKQ moderate Genetic Variation [29]
AQP5 OT77GBY8 moderate Genetic Variation [81]
ARNT OTMSIEZY moderate Altered Expression [29]
ATP5F1B OTLFZUQK moderate Altered Expression [82]
BICRA OTDTPGW0 moderate Genetic Variation [83]
C10orf53 OTAPN6SD moderate Biomarker [84]
CD81 OTQFXNAZ moderate Altered Expression [85]
CENPF OT7AG0SW moderate Biomarker [86]
CLDN5 OTUX60YO moderate Biomarker [87]
CLTCL1 OT6W5BNR moderate Biomarker [88]
COL5A1 OT24078H moderate Altered Expression [89]
CORO1A OTVAZOHC moderate Altered Expression [90]
CYC1 OT0962IM moderate Altered Expression [82]
DEFA5 OT95CBQ9 moderate Genetic Variation [20]
DHFR2 OTPHUWEY moderate Genetic Variation [91]
DSP OTB2MOP8 moderate Altered Expression [92]
EIF4A1 OTMTBX6N moderate Biomarker [93]
EIF4G1 OT2CF1E6 moderate Altered Expression [93]
ELAVL4 OT3YH6J6 moderate Biomarker [94]
EXOSC3 OTNCF906 moderate Altered Expression [95]
FAT3 OT3C6H8W moderate Biomarker [96]
FBLN1 OT5MHHOP moderate Biomarker [96]
GSC2 OT1CO9ED moderate Genetic Variation [97]
GSTM3 OTLA2WJT moderate Biomarker [98]
HIRA OTON40EJ moderate Genetic Variation [97]
HMGN5 OTUUAHVQ moderate Biomarker [99]
HOXA3 OTIX5XFB moderate Biomarker [22]
ITGA3 OTBCH21D moderate Biomarker [100]
KCNH6 OTQ52G7V moderate Biomarker [101]
LARGE1 OTUH7H9F moderate Biomarker [102]
LMO4 OT5NDCT9 moderate Biomarker [103]
LRRC4 OT7XJ70N moderate Altered Expression [104]
LTBP2 OTS88GSD moderate Biomarker [103]
MCM3 OTOOHQPM moderate Altered Expression [26]
MCM4 OT19PNNG moderate Biomarker [26]
MCM5 OTAHLB62 moderate Biomarker [26]
MLLT10 OTURMDV7 moderate Genetic Variation [105]
MLPH OT7ADCXL moderate Biomarker [96]
MMUT OTBBBV70 moderate Biomarker [26]
NDC1 OTF2GQC1 moderate Genetic Variation [106]
OGA OT7ZBWT1 moderate Altered Expression [107]
OGN OTKP5S4L moderate Biomarker [108]
OMD OTFRELBB moderate Biomarker [109]
PDLIM2 OTEURRPD moderate Biomarker [110]
RACGAP1 OTQE8IEH moderate Altered Expression [111]
RPL13A OTME3VXN moderate Altered Expression [82]
SEC31A OT2U42AC moderate Biomarker [112]
SRSF11 OTZSV6CZ moderate Biomarker [106]
TCEA1 OTBFO594 moderate Biomarker [112]
TCN2 OT41D0L3 moderate Biomarker [113]
TJP1 OTBDCUPK moderate Altered Expression [114]
TLE3 OTR9PH95 moderate Biomarker [115]
TMEM30B OTNSBH84 moderate Genetic Variation [116]
TSPAN12 OTF9I3CX moderate Biomarker [106]
TSPAN2 OTTDPQF1 moderate Genetic Variation [106]
ADAM23 OTVWT6JZ Strong Biomarker [117]
AQP4 OTA9MYD5 Strong Altered Expression [118]
ARID4B OTYLPILE Strong Biomarker [119]
ASL OTI2NGQR Strong Biomarker [120]
CD8A OTDWQJXK Strong Genetic Variation [39]
CETN2 OTJTTGS0 Strong Altered Expression [121]
CETN3 OTG4PL7H Strong Altered Expression [121]
DCT OTYVNTBG Strong Altered Expression [122]
DVL3 OTPRROHJ Strong Genetic Variation [123]
HNRNPC OT47AK4C Strong Altered Expression [124]
HNRNPDL OTB3BFCV Strong Altered Expression [124]
HOXA9 OTKNK5H0 Strong Biomarker [74]
ING2 OT6H0EWF Strong Genetic Variation [39]
KRIT1 OT58AP1I Strong Altered Expression [43]
MB OTYWYL2D Strong Genetic Variation [125]
MEN1 OTN6U6V0 Strong Biomarker [126]
MIA2 OTOGTUTU Strong Altered Expression [127]
MIB1 OT5C404P Strong Altered Expression [128]
MMP25 OT3BG37V Strong Altered Expression [129]
NDRG2 OT5L6KD7 Strong Posttranslational Modification [130]
NDRG4 OTJBOTD8 Strong Biomarker [131]
PIEZO1 OTBG1FU4 Strong Biomarker [132]
PRDM2 OT8L7CGX Strong Altered Expression [65]
PRELP OT9EEBUJ Strong Biomarker [133]
PROP1 OT8GF6N8 Strong Altered Expression [134]
PSMG1 OTZ5I6UM Strong Biomarker [135]
RANBP2 OTFG5CVF Strong Altered Expression [122]
RASAL1 OTAHUNN7 Strong Genetic Variation [136]
S100A1 OT1F2G4J Strong Biomarker [137]
SFRP1 OT0U9G41 Strong Altered Expression [138]
SP100 OTN8SD5W Strong Altered Expression [139]
SYNM OTOI8TRJ Strong Biomarker [140]
TIMP3 OTDGQAD1 Strong Biomarker [141]
TRAF7 OTW8Q5TF Strong Genetic Variation [33]
AP1B1 OTY0K84R Definitive Biomarker [142]
AP2B1 OTL6LZJ4 Definitive Genetic Variation [143]
BCR OTCN76C1 Definitive Biomarker [142]
CADM1 OTRWG9QS Definitive Biomarker [144]
CFL1 OTT6D5MH Definitive Genetic Variation [57]
CKS2 OTPTMHIV Definitive Biomarker [103]
CTAG1B OTIQGW6U Definitive Altered Expression [59]
DLC1 OTP8LMCR Definitive Altered Expression [145]
EEF1E1 OTRA6XOB Definitive Genetic Variation [57]
EIF4A2 OT08H03R Definitive Altered Expression [82]
EPB41 OTGCFPV8 Definitive Altered Expression [146]
EPB41L3 OTS6CHG2 Definitive Altered Expression [147]
FGF9 OT2SKDGM Definitive Altered Expression [19]
HES1 OT8P19W2 Definitive Biomarker [148]
IGF2BP1 OT9G360P Definitive Biomarker [149]
LAMTOR1 OTIBJBW9 Definitive Genetic Variation [57]
MAFK OTZJUE4P Definitive Genetic Variation [57]
MCM2 OTGGORIQ Definitive Biomarker [112]
MINDY4 OTBZ2SZB Definitive Biomarker [150]
POLR2A OTHJQ1DZ Definitive Genetic Variation [151]
PRAP1 OT48QD82 Definitive Posttranslational Modification [152]
PTTG1 OTIMYS4W Definitive Biomarker [153]
SMARCB1 OT2LP7LJ Definitive Genetic Variation [44]
TAT OT2CJ91O Definitive Biomarker [154]
TCHP OTVDMHSY Definitive Genetic Variation [155]
TPPP2 OTI3WA6X Definitive Genetic Variation [57]
------------------------------------------------------------------------------------
⏷ Show the Full List of 134 DOT(s)

References

1 Delta-aminolevulinic acid dehydratase polymorphism and risk of brain tumors in adults. Environ Health Perspect. 2005 Sep;113(9):1209-11.
2 EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.
3 Identification of KIF11 As a Novel Target in Meningioma.Cancers (Basel). 2019 Apr 15;11(4):545. doi: 10.3390/cancers11040545.
4 Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism.EBioMedicine. 2019 Feb;40:77-91. doi: 10.1016/j.ebiom.2018.12.048. Epub 2018 Dec 26.
5 Control of meningioma cell growth by platelet-derived growth factor (PDGF).J Neurol Sci. 1995 Aug;131(2):135-43. doi: 10.1016/0022-510x(95)00106-c.
6 The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells.J Neurooncol. 2007 May;83(1):9-15. doi: 10.1007/s11060-006-9301-3. Epub 2007 Jan 24.
7 Fluorescence imaging of meningioma cells with somatostatin receptor ligands: an in vitro study.Acta Neurochir (Wien). 2019 May;161(5):1017-1024. doi: 10.1007/s00701-019-03872-x. Epub 2019 Mar 15.
8 Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.World Neurosurg. 2020 Mar;135:e12-e18. doi: 10.1016/j.wneu.2019.10.044. Epub 2019 Oct 16.
9 Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma.Neoplasia. 2012 Jan;14(1):20-8. doi: 10.1593/neo.111574.
10 Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.J Neurosurg. 2010 May;112(5):940-50. doi: 10.3171/2009.7.JNS081729.
11 The role and regulatory mechanism of IL-1 on the methylation of the NF2 gene in benign meningiomas and leptomeninges.Mol Carcinog. 2016 Dec;55(12):2268-2277. doi: 10.1002/mc.22467. Epub 2016 Feb 3.
12 Advances in multidisciplinary therapy for meningiomas.Neuro Oncol. 2019 Jan 14;21(Suppl 1):i18-i31. doi: 10.1093/neuonc/noy136.
13 CASP8, XRCC1, WRN, NF2, and BRIP1 Polymorphisms Analysis Shows Their Genetic Susceptibility for Meningioma Risk and the Association with Tumor-Related Phenotype in a Chinese Population.World Neurosurg. 2018 Jun;114:e883-e891. doi: 10.1016/j.wneu.2018.03.108. Epub 2018 Mar 23.
14 Meningiomas expressing and responding to cholecystokinin (CCK).J Neurooncol. 2005 Jul;73(3):199-204. doi: 10.1007/s11060-004-5177-2.
15 CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors.Int J Cancer. 2002 Mar 20;98(3):352-6. doi: 10.1002/ijc.10207.
16 Pediatric infratentorial meningiomas: a series of 19 cases and review of the literature.Childs Nerv Syst. 2017 May;33(5):777-786. doi: 10.1007/s00381-017-3362-9. Epub 2017 Feb 28.
17 Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.Int J Oncol. 2010 Feb;36(2):351-8.
18 Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and EGFL6 overexpression in benign meningioma tissue and serum.PLoS One. 2012;7(12):e52707. doi: 10.1371/journal.pone.0052707. Epub 2012 Dec 28.
19 Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.Neurosurgery. 2008 Oct;63(4):771-80; discussion 780-1. doi: 10.1227/01.NEU.0000325488.72518.9E.
20 Risk of meningioma and common variation in genes related to innate immunity.Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1356-61. doi: 10.1158/1055-9965.EPI-09-1151. Epub 2010 Apr 20.
21 uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma.PLoS One. 2011 Feb 11;6(2):e17123. doi: 10.1371/journal.pone.0017123.
22 HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas.Transl Res. 2012 Nov;160(5):355-62. doi: 10.1016/j.trsl.2012.05.007. Epub 2012 Jun 23.
23 Altered tryptophan metabolism in human meningioma.J Neurooncol. 2016 Oct;130(1):69-77. doi: 10.1007/s11060-016-2225-7. Epub 2016 Jul 29.
24 Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.J Neurooncol. 2002 Mar;57(1):19-26. doi: 10.1023/a:1015765613544.
25 Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.Tumour Biol. 2012 Oct;33(5):1375-83. doi: 10.1007/s13277-012-0385-4. Epub 2012 Apr 3.
26 Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.J Proteome Res. 2010 Jan;9(1):485-94. doi: 10.1021/pr900834h.
27 Gene expression abnormalities in human glial tumors identified by gene array.Int J Oncol. 2001 Feb;18(2):287-95. doi: 10.3892/ijo.18.2.287.
28 Analysis of several PLA2 mRNA in human meningiomas.Mediators Inflamm. 2009;2009:689430. doi: 10.1155/2009/689430. Epub 2010 Mar 21.
29 Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma.J Neurooncol. 2018 Apr;137(2):241-248. doi: 10.1007/s11060-017-2730-3. Epub 2018 Jan 4.
30 Dopamine D1, dopamine D2, and prolactin receptor messenger ribonucleic acid expression by the polymerase chain reaction in human meningiomas.Neurosurgery. 1996 Feb;38(2):367-75. doi: 10.1097/00006123-199602000-00027.
31 Effect of TAGLN2 in the regulation of meningioma tumorigenesis and development.Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):307-313. doi: 10.26355/eurrev_201801_14173.
32 Chromosomal and genetic aberrations differ with meningioma subtype.Brain Tumor Pathol. 2004;21(3):127-33. doi: 10.1007/BF02482188.
33 Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.J Neurooncol. 2019 Aug;144(1):11-20. doi: 10.1007/s11060-019-03198-9. Epub 2019 Jun 8.
34 MAC30 knockdown involved in the activation of the Hippo signaling pathway in breast cancer cells.Biol Chem. 2018 Oct 25;399(11):1305-1311. doi: 10.1515/hsz-2018-0250.
35 Novel tankyrase-related gene detected with meningioma-specific sera.Clin Cancer Res. 2001 Jan;7(1):113-9.
36 Transient receptor potential vanilloid (TRPV) channel expression in meningiomas: prognostic and predictive significance.Virchows Arch. 2019 Jul;475(1):105-114. doi: 10.1007/s00428-019-02584-y. Epub 2019 May 22.
37 Proteomic data in meningiomas: post-proteomic analysis can reveal novel pathophysiological pathways.J Neurooncol. 2011 Sep;104(2):401-10. doi: 10.1007/s11060-010-0526-9. Epub 2011 Jan 11.
38 Correlation of expression pattern of aquaporin-1 in primary central nervous system tumors with tumor type, grade, proliferation, microvessel density, contrast-enhancement and perilesional edema.J Cancer Res Ther. 2012 Oct-Dec;8(4):571-7. doi: 10.4103/0973-1482.106542.
39 Search for mutations of the hRAD54 gene in sporadic meningiomas with deletion at 1p32.Mol Carcinog. 1999 Apr;24(4):300-4. doi: 10.1002/(sici)1098-2744(199904)24:4<300::aid-mc8>3.0.co;2-g.
40 Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.Am J Pathol. 2001 Aug;159(2):661-9. doi: 10.1016/S0002-9440(10)61737-3.
41 uPAR and cathepsin B shRNA impedes TGF-1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway.Cell Death Dis. 2012 Dec 6;3(12):e439. doi: 10.1038/cddis.2012.170.
42 MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia.J Clin Invest. 2016 Apr 1;126(4):1438-50. doi: 10.1172/JCI80825. Epub 2016 Feb 29.
43 Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers.Hum Pathol. 2004 Nov;35(11):1413-8. doi: 10.1016/j.humpath.2004.07.017.
44 Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas.J Neurosurg. 2019 Oct 25;133(5):1345-1354. doi: 10.3171/2019.8.JNS191266.
45 MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.J Neurooncol. 2017 Feb;131(3):575-583. doi: 10.1007/s11060-016-2329-0. Epub 2016 Nov 21.
46 Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis.Crit Rev Eukaryot Gene Expr. 2019;29(2):141-150. doi: 10.1615/CritRevEukaryotGeneExpr.2019025430.
47 Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors.J Neuropathol Exp Neurol. 2008 Aug;67(8):741-9. doi: 10.1097/NEN.0b013e318180e618.
48 Diagnostic impact of ornithine decarboxylase in meningiomas.J Neurooncol. 2004 Jan;66(1-2):59-64. doi: 10.1023/b:neon.0000013483.50955.2f.
49 Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.Onco Targets Ther. 2017 Apr 12;10:2077-2085. doi: 10.2147/OTT.S132964. eCollection 2017.
50 Prostate stem cell antigen is expressed in normal and malignant human brain tissues.Oncol Lett. 2018 Mar;15(3):3081-3084. doi: 10.3892/ol.2017.7632. Epub 2017 Dec 18.
51 Expression of Rac3 in human brain tumors.J Clin Neurosci. 2005 Jun;12(5):571-4. doi: 10.1016/j.jocn.2004.08.013.
52 Burosumab in tumor-induced osteomalacia: A case report.Joint Bone Spine. 2020 Jan;87(1):81-83. doi: 10.1016/j.jbspin.2019.07.012. Epub 2019 Aug 3.
53 Somatostatin Receptor 2 Expression in Canine Meningioma.J Comp Pathol. 2019 Jan;166:59-68. doi: 10.1016/j.jcpa.2018.11.002. Epub 2018 Dec 13.
54 Thioredoxin-Interact ing-Pro t e in [TXNIP] and Transglutaminase 2 [TGM2] Expression in Meningiomas of Different Grades and the Role of Their Expression in Meningioma Recurrence and Prognosis.Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2299-2308. doi: 10.22034/APJCP.2017.18.8.2299.
55 Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.J Neurooncol. 2018 Sep;139(2):469-478. doi: 10.1007/s11060-018-2891-8. Epub 2018 May 30.
56 Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases.Cytogenet Cell Genet. 2001;93(3-4):207-20. doi: 10.1159/000056986.
57 Molecular analysis of alterations of the p18INK4c gene in human meningiomas.Neuropathol Appl Neurobiol. 2000 Feb;26(1):67-75. doi: 10.1046/j.1365-2990.2000.00219.x.
58 Distinct Expression Patterns of Carbonic Anhydrase IX in Clear Cell, Microcystic, and Angiomatous Meningiomas.J Neuropathol Exp Neurol. 2019 Dec 1;78(12):1081-1088. doi: 10.1093/jnen/nlz091.
59 NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.Cancer Immunol Res. 2013 Nov;1(5):296-302. doi: 10.1158/2326-6066.CIR-13-0029. Epub 2013 Aug 5.
60 Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma.Prostate Cancer Prostatic Dis. 2013 Dec;16(4):387-90. doi: 10.1038/pcan.2013.45. Epub 2013 Oct 8.
61 The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence.J Mol Endocrinol. 2007 Feb;38(1-2):113-25. doi: 10.1677/jme.1.02110.
62 Overexpression of midkine contributes to anti-apoptotic effects in human meningiomas.J Neurochem. 2007 Feb;100(4):1097-107. doi: 10.1111/j.1471-4159.2006.04276.x. Epub 2006 Dec 20.
63 Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.J Neurol Sci. 2020 Jan 15;408:116553. doi: 10.1016/j.jns.2019.116553. Epub 2019 Nov 9.
64 Functional significance of S6K overexpression in meningioma progression.Ann Neurol. 2004 Aug;56(2):295-8. doi: 10.1002/ana.20201.
65 Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.Int J Clin Oncol. 2017 Aug;22(4):660-666. doi: 10.1007/s10147-017-1103-4. Epub 2017 Feb 27.
66 Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging.J Neurooncol. 2019 Sep;144(2):275-282. doi: 10.1007/s11060-019-03205-z. Epub 2019 Aug 10.
67 Immunohistochemical study of MRP5 expression in meningiomas.Cancer Chemother Pharmacol. 2013 Mar;71(3):825-8. doi: 10.1007/s00280-012-2057-x. Epub 2012 Dec 28.
68 Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci.Cancer Res. 1995 Oct 1;55(19):4237-9.
69 Folate metabolism genetic polymorphisms and meningioma and glioma susceptibility in adults.Oncotarget. 2017 Jul 4;8(34):57265-57277. doi: 10.18632/oncotarget.18986. eCollection 2017 Aug 22.
70 PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.Oncotarget. 2015 Oct 20;6(32):32713-22. doi: 10.18632/oncotarget.5296.
71 First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.BMC Cancer. 2017 Feb 13;17(1):127. doi: 10.1186/s12885-017-3127-6.
72 Analysis of ARMC5 expression in human tissues.Mol Cell Endocrinol. 2017 Feb 5;441:140-145. doi: 10.1016/j.mce.2016.08.018. Epub 2016 Aug 24.
73 Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21715-21726. doi: 10.1073/pnas.1912858116. Epub 2019 Oct 7.
74 Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia.Haematologica. 2020 May;105(5):1294-1305. doi: 10.3324/haematol.2018.211201. Epub 2019 Aug 14.
75 Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.Glia. 1995 Nov;15(3):297-307. doi: 10.1002/glia.440150310.
76 Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.Neuro Oncol. 2018 Jul 5;20(8):1122-1132. doi: 10.1093/neuonc/nox228.
77 SNHG1/miR-556-5p/TCF12 feedback loop enhances the tumorigenesis of meningioma through Wnt signaling pathway.J Cell Biochem. 2020 Feb;121(2):1880-1889. doi: 10.1002/jcb.29423. Epub 2019 Nov 6.
78 Clinicopathological and molecular characteristics of pediatric meningiomas.Neuropathology. 2018 Feb;38(1):22-33. doi: 10.1111/neup.12426. Epub 2017 Sep 13.
79 Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor.Pituitary. 2012 Dec;15 Suppl 1:S61-7. doi: 10.1007/s11102-012-0391-y.
80 Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression.Sci Rep. 2018 Feb 1;8(1):2098. doi: 10.1038/s41598-018-19308-y.
81 Expression of aquaporin 5 and the AQP5 polymorphism A(-1364)C in association with peritumoral brain edema in meningioma patients.J Neurooncol. 2013 Apr;112(2):297-305. doi: 10.1007/s11060-013-1064-z. Epub 2013 Feb 8.
82 Validation of Reference Genes for Expression Studies in Human Meningiomas under Different Experimental Settings.Mol Neurobiol. 2018 Jul;55(7):5787-5797. doi: 10.1007/s12035-017-0800-3. Epub 2017 Oct 27.
83 DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.Neuro Oncol. 2010 Jan;12(1):37-48. doi: 10.1093/neuonc/nop012. Epub 2009 Dec 10.
84 Whole exome sequencing in a case of sporadic multiple meningioma reveals shared NF2, FAM109B, and TPRXL mutations, together with unique SMARCB1 alterations in a subset of tumor nodules.Cancer Genet. 2015 Jun;208(6):327-32. doi: 10.1016/j.cancergen.2015.03.012. Epub 2015 Apr 11.
85 The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups.Neuropathol Appl Neurobiol. 2015 Apr;41(3):319-32. doi: 10.1111/nan.12127.
86 DNA topoisomerase II and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.PLoS One. 2017 Mar 16;12(3):e0172316. doi: 10.1371/journal.pone.0172316. eCollection 2017.
87 Modulation of Dkk-3 and claudin-5 as new therapeutic strategy in the treatment of meningiomas.Oncotarget. 2017 Aug 7;8(40):68280-68290. doi: 10.18632/oncotarget.20047. eCollection 2017 Sep 15.
88 Characterization of a second human clathrin heavy chain polypeptide gene (CLH-22) from chromosome 22q11.Hum Mol Genet. 1996 May;5(5):625-31. doi: 10.1093/hmg/5.5.625.
89 miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.Oncogene. 2013 Sep 26;32(39):4712-20. doi: 10.1038/onc.2012.468. Epub 2012 Oct 29.
90 Expression, correlation and prognostic significance of CD133, P57 and HSF1 in meningioma.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4600-4605.
91 Polymorphisms of methionine metabolism and susceptibility to meningioma formation: laboratory investigation.J Neurosurg. 2008 May;108(5):999-1004. doi: 10.3171/JNS/2008/108/5/0999.
92 A genetic strategy to overcome the senescence of primary meningioma cell cultures.J Neurooncol. 2006 Jun;78(2):113-21. doi: 10.1007/s11060-005-9076-y. Epub 2006 Mar 23.
93 Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.Exp Neurol. 2018 Jan;299(Pt B):299-307. doi: 10.1016/j.expneurol.2017.06.015. Epub 2017 Jun 10.
94 Reduced expression of ELAVL4 in male meningioma patients.Brain Tumor Pathol. 2013 Jul;30(3):160-6. doi: 10.1007/s10014-012-0117-x. Epub 2012 Sep 11.
95 Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.J Neurooncol. 2001 Dec;55(3):149-58. doi: 10.1023/a:1013863630293.
96 Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.Int J Oncol. 2009 Dec;35(6):1395-407. doi: 10.3892/ijo_00000457.
97 Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray.Neurol Res. 2005 Oct;27(7):747-54. doi: 10.1179/016164105X35648.
98 Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors.Neuro Oncol. 2006 Apr;8(2):145-55. doi: 10.1215/15228517-2005-003. Epub 2006 Jan 27.
99 HMGN5 blockade by siRNA enhances apoptosis, suppresses invasion and increases chemosensitivity to temozolomide in meningiomas.Int J Oncol. 2015 Oct;47(4):1503-11. doi: 10.3892/ijo.2015.3131. Epub 2015 Aug 25.
100 [Expression of integrin-alpha 3 mRNA in meningiomas and its biological significance].Ai Zheng. 2002 May;21(5):526-9.
101 MicroRNA-224 targets ERG2 and contributes to malignant progressions of meningioma.Biochem Biophys Res Commun. 2015 May 1;460(2):354-61. doi: 10.1016/j.bbrc.2015.03.038. Epub 2015 Mar 14.
102 The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family.Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):598-603. doi: 10.1073/pnas.96.2.598.
103 Genetic alterations associated with progression and recurrence in meningiomas.J Neuropathol Exp Neurol. 2012 Oct;71(10):882-93. doi: 10.1097/NEN.0b013e31826bf704.
104 LRRC4 haplotypes are associated with pituitary adenoma in a Chinese population.Med Oncol. 2014 Apr;31(4):888. doi: 10.1007/s12032-014-0888-5. Epub 2014 Feb 23.
105 Brain tumor risk according to germ-line variation in the MLLT10 locus.Eur J Hum Genet. 2015 Jan;23(1):132-4. doi: 10.1038/ejhg.2014.70. Epub 2014 Apr 23.
106 A comparison of the prevalence and risk factors of complications in intracranial tumor embolization between the Japanese Registry of NeuroEndovascular Therapy 2 (JR-NET2) and JR-NET3.Acta Neurochir (Wien). 2019 Aug;161(8):1675-1682. doi: 10.1007/s00701-019-03970-w. Epub 2019 Jun 7.
107 Novel immunogenic antigen homologous to hyaluronidase in meningioma.Hum Mol Genet. 1998 Nov;7(12):1859-72. doi: 10.1093/hmg/7.12.1859.
108 Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.Cell Commun Signal. 2017 Sep 18;15(1):34. doi: 10.1186/s12964-017-0189-7.
109 Genetic alterations in meningiomas of different textures.Gene. 2016 Oct 30;592(1):134-139. doi: 10.1016/j.gene.2016.07.057. Epub 2016 Jul 27.
110 Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.EBioMedicine. 2017 Feb;16:76-86. doi: 10.1016/j.ebiom.2017.01.020. Epub 2017 Jan 18.
111 Expression of RACGAP1 in high grade meningiomas: a potential role in cancer progression.J Neurooncol. 2013 Jun;113(2):327-32. doi: 10.1007/s11060-013-1121-7. Epub 2013 Mar 25.
112 Meningioma protein-protein interaction network.Arch Iran Med. 2014 Apr;17(4):262-72.
113 Assignment of human transcobalamin II (TC2) to chromosome 22 using somatic cell hybrids and monosomic meningioma cells.Hum Genet. 1986 Dec;74(4):378-81. doi: 10.1007/BF00280489.
114 Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas.J Neurol Sci. 2017 Sep 15;380:112-121. doi: 10.1016/j.jns.2017.07.009. Epub 2017 Jul 8.
115 Meningioma transcript profiles reveal deregulated Notch signaling pathway.Cancer Res. 2005 Jun 15;65(12):5070-5. doi: 10.1158/0008-5472.CAN-05-0240.
116 Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.Neuro Oncol. 2010 Dec;12(12):1278-90. doi: 10.1093/neuonc/noq081. Epub 2010 Aug 4.
117 ADAM23 methylation and expression analysis in brain tumors.Neurosci Lett. 2005 Jun 3;380(3):260-4. doi: 10.1016/j.neulet.2005.01.050. Epub 2005 Feb 8.
118 Correlation Between Aquaporin 4 Expression and Different DWI Parameters in Grade I Meningioma.Mol Imaging Biol. 2017 Feb;19(1):138-142. doi: 10.1007/s11307-016-0978-1.
119 ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas.J Clin Pathol. 2017 Feb;70(2):162-167. doi: 10.1136/jclinpath-2016-203804. Epub 2016 Jul 22.
120 Arterial spin-labeling is useful for the diagnosis of residual or recurrent meningiomas.Eur Radiol. 2018 Oct;28(10):4334-4342. doi: 10.1007/s00330-018-5404-4. Epub 2018 Apr 13.
121 Differential expression of centrosome-associated proteins in human brain tumors: a possible role of hNinein isoform 6 in cell differentiation.Biofactors. 2012 Nov-Dec;38(6):470-7. doi: 10.1002/biof.1053. Epub 2012 Oct 10.
122 Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma.J Clin Neurosci. 2012 Jul;19(7):1016-21. doi: 10.1016/j.jocn.2011.10.008. Epub 2012 Apr 23.
123 Genetic changes of MLH1 and MSH2 genes could explain constant findings on microsatellite instability in intracranial meningioma.Tumour Biol. 2017 Jul;39(7):1010428317705791. doi: 10.1177/1010428317705791.
124 LGR5 and Downstream Intracellular Signaling Proteins Play Critical Roles in the Cell Proliferation of Neuroblastoma, Meningioma and Pituitary Adenoma.Exp Neurobiol. 2019 Oct 31;28(5):628-641. doi: 10.5607/en.2019.28.5.628.
125 Cosmid mapping and locus linkage within the human chromosomal region 22q13.1.Cancer Genet Cytogenet. 1993 Oct 15;70(2):108-11. doi: 10.1016/0165-4608(93)90177-n.
126 Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia.J Pathol. 2017 Aug;242(4):421-434. doi: 10.1002/path.4916. Epub 2017 Jul 5.
127 MEA6 Deficiency Impairs Cerebellar Development and Motor Performance by Tethering Protein Trafficking.Front Cell Neurosci. 2019 Jun 11;13:250. doi: 10.3389/fncel.2019.00250. eCollection 2019.
128 WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma.Acta Neurochir (Wien). 2019 Dec;161(12):2553-2561. doi: 10.1007/s00701-019-04084-z. Epub 2019 Oct 21.
129 Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors.Cancer Res. 2000 Feb 15;60(4):877-82.
130 Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.Clin Transl Oncol. 2020 Jul;22(7):1138-1145. doi: 10.1007/s12094-019-02240-6. Epub 2019 Nov 15.
131 Nervous NDRGs: the N-myc downstream-regulated gene family in the central and peripheral nervous system.Neurogenetics. 2019 Oct;20(4):173-186. doi: 10.1007/s10048-019-00587-0. Epub 2019 Sep 4.
132 Chromosomal losses and gains in meningiomas: comparative genomic hybridization (CGH) study of the whole genome.Neurol Res. 1998 Oct;20(7):612-6. doi: 10.1080/01616412.1998.11740572.
133 Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies.OMICS. 2010 Apr;14(2):157-64. doi: 10.1089/omi.2009.0093.
134 Prop-1 gene expression in human pituitary tumors.J Clin Endocrinol Metab. 1999 Jul;84(7):2581-4. doi: 10.1210/jcem.84.7.5974.
135 Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain Cancers.Front Oncol. 2019 Feb 25;9:96. doi: 10.3389/fonc.2019.00096. eCollection 2019.
136 Medullary thyroid cancer, leukemia, mesothelioma and meningioma associated with germline APC and RASAL1 variants: a new syndrome?.Hormones (Athens). 2017 Oct;16(4):423-428. doi: 10.14310/horm.2002.1763.
137 Meningiomas Display a Specific Immunoexpression Pattern in a Rostrocaudal Gradient: An Analysis of 366 Patients.World Neurosurg. 2019 Mar;123:e520-e535. doi: 10.1016/j.wneu.2018.11.201. Epub 2018 Nov 29.
138 AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.Acta Neuropathol. 2013 Nov;126(5):757-62. doi: 10.1007/s00401-013-1187-5. Epub 2013 Oct 6.
139 SP100 reduces malignancy of human glioma cells.Int J Oncol. 2011 Apr;38(4):1023-30. doi: 10.3892/ijo.2011.927. Epub 2011 Jan 27.
140 Task-evoked reconfiguration of the fronto-parietal network is associated with cognitive performance in brain tumor patients.Brain Imaging Behav. 2020 Dec;14(6):2351-2366. doi: 10.1007/s11682-019-00189-2.
141 Genetic and epigenetic alterations in meningiomas.Clin Neurol Neurosurg. 2017 Jul;158:119-125. doi: 10.1016/j.clineuro.2017.05.002. Epub 2017 May 3.
142 Pathological classification and molecular genetics of meningiomas.J Neurooncol. 2010 Sep;99(3):379-91. doi: 10.1007/s11060-010-0342-2. Epub 2010 Sep 1.
143 Structure of the promoter and genomic organization of the human beta'-adaptin gene (BAM22) from chromosome 22q12.Genomics. 1996 Aug 15;36(1):112-7. doi: 10.1006/geno.1996.0431.
144 Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor.Neurology. 2006 Nov 28;67(10):1863-6. doi: 10.1212/01.wnl.0000244472.56198.84.
145 Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.J Neurooncol. 2016 Dec;130(3):473-484. doi: 10.1007/s11060-016-2261-3. Epub 2016 Sep 10.
146 GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis.Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7. doi: 10.1016/j.cancergencyto.2005.02.009.
147 Pivotal roles of protein 4.1B/DAL?, a FERMdomain containing protein, in tumor progression (Review).Int J Oncol. 2019 Nov;55(5):979-987. doi: 10.3892/ijo.2019.4877. Epub 2019 Sep 13.
148 Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres.Genes Cancer. 2010 Aug;1(8):822-35. doi: 10.1177/1947601910383564.
149 Methylation markers of malignant potential in meningiomas.J Neurosurg. 2013 Oct;119(4):899-906. doi: 10.3171/2013.7.JNS13311. Epub 2013 Aug 9.
150 Atypical cystic meningioma overexpressing AQP1 in early infancy: case report with literature review.Acta Paediatr. 2008 Aug;97(8):1145-9. doi: 10.1111/j.1651-2227.2008.00877.x. Epub 2008 May 21.
151 Clinical potential of meningioma genomic insights: a practical review for neurosurgeons.Neurosurg Focus. 2018 Jun;44(6):E10. doi: 10.3171/2018.2.FOCUS1849.
152 Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.Neoplasia. 2013 Feb;15(2):192-203. doi: 10.1593/neo.121334.
153 PTTG-1 (Securin) immunoexpression in meningiomas correlates with tumor grade and proliferation rate: potential use as a diagnostic marker of malignancy.APMIS. 2018 Apr;126(4):295-302. doi: 10.1111/apm.12825.
154 Holistic and network analysis of meningioma pathogenesis and malignancy.Biofactors. 2006;28(3-4):203-19. doi: 10.1002/biof.5520280307.
155 Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression.Oncogene. 2004 Apr 29;23(20):3589-96. doi: 10.1038/sj.onc.1207445.